For the Inventor, By the Inventor

Enter assignee name

Cambridge, United Kingdom

Cambridge Antibody Technology Limited

USPTO Granted Patents = 28

CIPO Patents = 3

EPO Patents = 4

Forward Citations = 4,986

Loading Chart...

Loading Chart...

63 inventors (with patents filed for the assignee):

Gregory Paul Winter (14 out of 75 patents)

Kevin Stuart Johnson (14 out of 25 patents)

John Gerald McCafferty (12 out of 30 patents)

4. Andrew David Griffiths (11 out of 59 patents)

5. Tristan J Vaughan (7 out of 33 patents)

6. James David Marks (6 out of 81 patents)

7. Alison Jane Wilton (5 out of 20 patents)

8. Anthony Richard Pope (5 out of 13 patents)

9. Jane Katharine Osbourn (5 out of 5 patents)

10. Andrew John Smith (5 out of 5 patents)

11. Elaine Joy Derbyshire (4 out of 10 patents)

12. Andrew James Williams (4 out of 6 patents)

13. Philip Ronald Tempest (4 out of 19 patents)

14. Ronald Henry Jackson (4 out of 13 patents)

15. Peter Michael Waterhouse (3 out of 23 patents)

28 patents: Sort by Forward Citations

1. 7495085 - Antibodies against human or mouse IL-21 receptor (2009-02-24),

2. 7368111 - Human antibodies specific for TGFβ2 (2008-05-06),

3. 7323311 - Methods of obtaining a specific binding member that binds eotaxin (2008-01-29),

4. 7306907 - Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors (2007-12-11),

5. 7261893 - Neutralizing antibodies against GDF-8 and uses therefor (2007-08-28),

6. 7195866 - Production of anti-self antibodies from antibody segment repertoires and displayed on phage (2007-03-27),

7. 7151169 - [object Object] (2006-12-19),

8. 7074557 - Ribosome display (2006-07-11),

9. 7063943 - Methods for producing members of specific binding pairs (2006-06-20),

10. 6946546 - Human antibodies against eotaxin (2005-09-20),

11. 6916605 - Methods for producing members of specific binding pairs (2005-07-12),

12. 6827925 - Specific binding proteins including antibodies which bind to the necrotic center of tumors, and uses thereof (2004-12-07),

13. 6492497 - Specific binding members for TGFbeta1 (2002-12-10),

14. 6489123 - Labelling and selection of molecules (2002-12-03),

15. 6342588 - Labelling and selection of molecules (2002-01-29),

Cambridge Antibody Technology Limited (CAT) is a biotechnology company based in Cambridge, UK. CAT specializes in the discovery and development of human monoclonal antibodies using phage display technology. The company offers a wide range of therapeutic antibody products and services for the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. CAT has a strong track record in successful partnerships and collaborations with pharmaceutical companies worldwide. Visit their website to learn more about their innovative antibody-based solutions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

28 Patents

#35 in Cambridge

#635 in United Kingdom

#22,565 in the World

Cambridge, United Kingdom

Cambridge Antibody Technology Limited

Forward Citations = 4,986

63 inventors:

Gregory Paul Winter (14 out of 75 patents)

Kevin Stuart Johnson (14 out of 25 patents)

John Gerald McCafferty (12 out of 30 patents)

4. Andrew David Griffiths (11 out of 59 patents)

5. Tristan J Vaughan (7 out of 33 patents)

Please report any incorrect information to support@idiyas.com

Loading…